Global Medical REIT Inc. (NYSE:XRN – Get Free Report) Director Matthew Cypher purchased 1,420 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average cost of $35.12 per share, with a total value of $49,870.40. Following the completion of the transaction, the director owned 1,690 shares of the company’s stock, valued at approximately $59,352.80. The trade was a 525.93% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Global Medical REIT Stock Down 3.0%
Shares of XRN stock traded down $1.04 during mid-day trading on Friday, hitting $33.54. 113,693 shares of the stock traded hands, compared to its average volume of 121,182. The stock has a market cap of $443.68 million, a P/E ratio of -30.21 and a beta of 1.11. The stock’s fifty day moving average is $34.98 and its two-hundred day moving average is $34.47. Global Medical REIT Inc. has a 52-week low of $29.05 and a 52-week high of $39.93. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.68 and a quick ratio of 0.61.
Global Medical REIT Announces Dividend
The company also recently declared a monthly dividend, which will be paid on Friday, September 18th. Shareholders of record on Thursday, August 20th will be given a dividend of $0.16 per share. This represents a c) annualized dividend and a dividend yield of 5.7%. The ex-dividend date of this dividend is Thursday, August 20th. Global Medical REIT’s dividend payout ratio is presently -270.27%.
Hedge Funds Weigh In On Global Medical REIT
Analyst Ratings Changes
Several research firms have commented on XRN. Weiss Ratings lowered shares of Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Wall Street Zen lowered shares of Global Medical REIT from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Compass Point restated a “neutral” rating and set a $38.00 price objective (down from $50.00) on shares of Global Medical REIT in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $39.67.
Check Out Our Latest Stock Analysis on XRN
Global Medical REIT Company Profile
Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.
Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.
Featured Articles
- Five stocks we like better than Global Medical REIT
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Global Medical REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT and related companies with MarketBeat.com's FREE daily email newsletter.
